6 / 18
Page 35
Notes:
allied
academies
Journal of Biomedical Research | ISSN: 0976-1683 | Volume 30
March 14-15, 2019 | London, UK
T issue Engineer ing, Stem Cel ls and Regenerat ive Medicine
Cel l and Gene Therapy
World Congress on
International Conference on
&
Joint Event
Senolytic effect of dasatinib and quercetin on human beings
Jaba Tkemaladze
Longevity Alliance, Georgia
S
enescent cells are the last generation of cell differentiation.
If programmed cell death (apoptosis) is not activated, then it
becomes the main source of intoxication for organism. After 36
years their amount is so great, that signs of aging start strongly
manifesting. For many years, scientists try to find combination
of substances that could kill part of senescent cells. In our
experiment we examine the senolytic effect of dasatinib and
quercetin on people. Dasatinib is a treatment for oncology
diseases, especially widely used when other treatments are
no longer working. Quercetin is the vitamin from bioflavonoid
group. So as to assess the anti-aging effect of dasatinib and
quercetin, we went through clinical trial. For this trial we
picked up certain volunteers. Our volunteers were only men
participants in spectrum of middle and old ages (36-40 y.o.).
We eliminated all female participants, because mutagenous
impact of dasatinib on ovicells is not examined properly. As
for the male-participants they were recommended to avoid
fertilization for the first 3 months after the clinical trial.
Generally, 64 men took part in our clinical trial. We classified
all these participants into 4 groups, by 16 people for each
group. First group of participants had to orally administer 50mg
of dasatinib along with 500 mg of quercetin; second group of
participants orally administered 50mg of dasatinib and 500 mg
of placebo; while third group also took quercetin and placebo,
but with different oral dose namely 500mg of quercetin along
with 50mg of placebo. The participants of fourth group orally
administered two compounds, and both were placebo with
a dosage of 500mg and 50mg. These participants of 4 groups
must orally administer these compounds once a day after meal
for 5 days overall.
For the accurate assessment of anti-aging effect of all
compounds stair ascending test was done by participants a day
prior to the start of trial and 21 days after the end of trial along
with medical screening each time. Complete blood count was
performed on participants all this time, and also since the start
of the test participants’ blood pressure was measured each 10
minutes with 3 overall estimates.
By the end of the trial with the help of all the gathered data it
was possible to make a solid conclusion, namely among all four
group the first group of participants who orally administered
50mg of dasatinib and 500mg of quercetin demonstrated
remarkably outstanding improvement of physical endurance
as compared to the rest of the groups. The simultaneous oral
administration of dasatinib (50mg) and quercetin (500mg)
showcased obvious senolytic (anti-aging) effect.
Speaker Biography
Jaba Tkemaladze was previously working as a research scientist at State Institute of
Morphology, TV Anchor at Georgian Public Broadcasting, adviser at The Ministry of
Defense of Georgia, and research scientist at Georgian Mental Health Coalition. His
papers include programming and implementation of age-related changes, gerontology
research in Georgia, potential role of centrioles in determining the morphogenetic status
of animal somatic cells, centriolar mechanisms of differentiation and replicative aging of
higher animal cell, centrosomal hypothesis of cellular aging and differentiation, discovery
of centrosomal RNA and centrosomal hypothesis of cellular aging and differentiation and
centriole, differentiation, and senescence. Jaba was graduate of medicine at State Medical
Institute in 1995 with the dissertation “Centriolar theory at age related changes”. His
researches include embryogenesis and radical rejuvenation. He got PhD in Psychology at
the Scientific Research Institute of Psychiatry in 1995 with the dissertation “Senescence,
psychosis, cancer”. Currently, he is CEO of Longevity Alliance of Georgia.
e:
djabbat@gmail.comJaba Tkemaladze
, Biomed Res, Volume 30
DOI: 10.4066/biomedicalresearch-C1-026